Scarica l'app Stockscreener
0.6401
7.23%
-0.0499
Dopo l'orario di chiusura:
.63
-0.0101
-1.58%
Precedente Chiudi:
$0.69
Aprire:
$0.66
Volume 24 ore:
293.72K
Relative Volume:
0.64
Capitalizzazione di mercato:
$3.48M
Reddito:
-
Utile/perdita netta:
$-14.07M
Rapporto P/E:
-0.0458
EPS:
-13.99
Flusso di cassa netto:
$-12.56M
1 W Prestazione:
-8.12%
1M Prestazione:
-12.33%
6M Prestazione:
-63.84%
1 anno Prestazione:
-85.90%
Intervallo 1D:
$0.63
$0.6698
Intervallo di 1 settimana:
$0.63
$0.7492
Portata 52W:
$0.60
$5.15
Palisade Bio Inc Stock (PALI) Company Profile
Nome
Palisade Bio Inc
Settore
Industria
Telefono
(858) 704-4900
Indirizzo
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Confronta PALI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
0.6401 | 3.48M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Palisade Bio Inc Borsa (PALI) Ultime notizie
Transpire Bio licenses rights to Intragrand’s PDE4 inhibitor ITG-1052 - BioWorld MedTech
GEN Restaurant Group, Inc. (NASDAQ:GENK) Shares Acquired by Northern Trust Corp - Defense World
Ameriprise Financial Inc. Sells 72,453 Shares of Eni S.p.A. (NYSE:E) - Defense World
The Wharf (Holdings) Limited (OTCMKTS:WARFY) Short Interest Up 27.0% in May - Defense World
Ameriprise Financial Inc. Sells 46,682 Shares of Brookfield Renewable Co. (NYSE:BEPC) - Defense World
Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH) Shares Purchased by Ameriprise Financial Inc. - Defense World
Yankuang Energy Group Company Limited (OTCMKTS:YZCAY) Short Interest Up 25.0% in May - Defense World
BOE Varitronix Limited (OTCMKTS:VARXF) Short Interest Update - Defense World
U.S. Global Jets ETF (NYSEARCA:JETS) Shares Sold by Ameriprise Financial Inc. - Defense World
Riverside Resources (OTCMKTS:RVSDF) Stock Price Down 9.3% – Should You Sell? - Defense World
Clune & Associates LTD. Invests $7.30 Million in Apple Inc. (NASDAQ:AAPL) - Defense World
5,157 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Bought by Northern Trust Corp - Defense World
Northern Trust Corp Raises Holdings in Key Tronic Co. (NASDAQ:KTCC) - Defense World
Ameriprise Financial Inc. Purchases New Position in Quantum Computing Inc. (NASDAQ:QUBT) - Defense World
Cetera Investment Advisers Purchases Shares of 70,006 Palisade Bio, Inc. (NASDAQ:PALI) - Defense World
Nuvation Bio’s (NUVB) “Market Outperform” Rating Reaffirmed at JMP Securities - Defense World
Ameriprise Financial Inc. Boosts Stake in BlackRock California Municipal Income Trust (NYSE:BFZ) - Defense World
Northern Trust Corp Acquires New Shares in iShares 10-20 Year Treasury Bond ETF (NYSEARCA:TLH) - Defense World
Torrid Holdings Inc. (NYSE:CURV) Shares Purchased by Bank of America Corp DE - Defense World
TPI Composites, Inc. (NASDAQ:TPIC) Shares Acquired by Bank of America Corp DE - Defense World
Palisade Bio Reports Improved Quarterly Losses - TipRanks
BNP Paribas Financial Markets Increases Position in Community West Bancshares (NASDAQ:CWBC) - Defense World
Palisade Bio (PALI) Reports Positive Phase 1 Results for PALI-21 - GuruFocus
Palisade Bio reports positive Phase 1 results for new drug By Investing.com - Investing.com South Africa
Palisade Bio Reports Positive Topline Data From Phase 1 Studies Of PALI-2108 - Nasdaq
Palatin Technologies (PALI) Teams Up with Key Managers for Inves - GuruFocus
Palisade Bio (PALI) Reports Positive Phase 1 Results for PALI-2108 | PALI Stock News - GuruFocus
Palatin Technologies (PALI) Teams Up with Key Managers for Investment Strategy | PALI Stock News - GuruFocus
Digital Ally, Inc. Sets Date to Discuss First Quarter 2025 Earnings Call Wednesday, May 28, 2025 at 11:15 a.m. Eastern Time - The Manila Times
Palisade Bio reports positive Phase 1 results for new drug - Investing.com
Palisade Bio Reports Positive Phase 1a Results for - GlobeNewswire
Breakthrough in Crohn's Disease Treatment: New Drug PALI-2108 Achieves Perfect Safety Profile in Phase 1 Trial - Stock Titan
Seneca Biopharma : Announces Update on Phase II Clinical Trial Underway in China for the Treatment of Ischemic Stroke - marketscreener.com
Palisade Bio Q2 EPS Lifted by Brookline Capital Management - Defense World
Palisade Bio (NASDAQ:PALI) Earns “Buy” Rating from Brookline Capital Management - Defense World
Palisade Bio (PALI) Receives Buy Rating from Brookline Capital | - GuruFocus
Palisade Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Palisade Bio (PALI) Receives Buy Rating from Brookline Capital | PALI Stock News - GuruFocus
PALISADE BIO, INC. SEC 10-Q Report - TradingView
PALI stock plunges to 52-week low, touches $1.34 - MSN
Palisade Bio reports positive data for UC drug trial - MSN
Palisade Bio (PALI) Projected to Post Quarterly Earnings on Monday - Defense World
Palisade Bio’s PALI-2108 shows promise in ulcerative colitis study - Investing.com
PALI Reports Positive Preclinical Outcomes for Ulcerative Colitis Treatment | PALI Stock News - GuruFocus
Palisade Bio’s PALI-2108 shows promise in ulcerative colitis study By Investing.com - Investing.com Canada
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases - GlobeNewswire
New Ulcerative Colitis Drug PALI-2108 Outperforms Standard Treatments in Crucial Disease Models - Stock Titan
Analyzing Palisade Bio (NASDAQ:PALI) and Ginkgo Bioworks (NYSE:DNA) - Defense World
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and - GlobeNewswire
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit - Stock Titan
FY2025 EPS Estimates for Palisade Bio Increased by Analyst - American Banking and Market News
Palisade Bio Inc Azioni (PALI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):